Drug Profile
Lutetium-177-labelled bombesin analogue
Alternative Names: 177Lu-AMBALatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bracco
- Developer Bracco; Marillion Pharmaceuticals
- Class Lanthanoid series elements; Peptide hormones
- Mechanism of Action Bombesin receptor agonists; Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer; Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Prostate-cancer in Europe (IV)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer(Late-stage disease, Metastatic disease) in USA (IV)
- 12 Nov 2008 Lutetium-177-labelled bombesin analogue licensed to Marillion Pharmaceuticals worldwide for the treatment of hormone-resistant prostate and metastatic breast cancers